Contact Levi & Korsinsky by September 30, 2025 Deadline to Join Class Action Against Novo Nordisk A/S(NVO)

Core Viewpoint - A class action securities lawsuit has been filed against Novo Nordisk A/S, alleging securities fraud that negatively impacted investors between May 7, 2025, and July 28, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Novo Nordisk made misleading statements about its growth potential, particularly regarding the compounded GLP-1 market and the likelihood of patients switching to its branded products [2]. - On July 29, 2025, Novo Nordisk lowered its sales and profit outlook for the second half of 2025, attributing this to lower growth expectations for its products Wegovy and Ozempic, compounded GLP-1 usage, and increased competition [2]. - Following the announcement, Novo's stock price dropped from $69.00 per share on July 28, 2025, to $53.94 per share on July 29, 2025, marking a decline of approximately 21.83% in one day [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until September 30, 2025, to request to be appointed as lead plaintiff in the lawsuit [3]. - Participation in the lawsuit does not require any out-of-pocket costs or fees for class members [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4].